Spero Therapeutics, Inc. (SPRO)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Ms. Esther P. Rajavelu
|
CEO, President, CFO, Chief Business Officer, Treasurer & Director | 1.65M | -- | 1979 |
|
Mr. Timothy Keutzer
|
Chief Operating Officer | 1.23M | -- | 1968 |
|
Mr. John Raymond
|
Senior Vice President of Finance & Business Operations | -- | -- | -- |
|
Dr. Debra Jeske Zack M.D., Ph.D.
|
Chief Medical Officer | -- | -- | 1957 |
Spero Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 25
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
November 12, 2026 at 8:00 PM UTC
Spero Therapeutics, Inc. Earnings Date
